Soru

Zorluk: OrtaPreventive Care and Screening

An occupational health physician evaluates a 28-year-old woman who is preparing to begin employment as a clinical laboratory technician, a role that involves handling human blood samples. She has a medical history of severe plaque psoriasis, which has been well controlled since initiating treatment with subcutaneous adalimumab six months ago. She has no other medical conditions. She has never smoked cigarettes and consumes alcohol occasionally. Her last cervical cancer screening with cytology was one year ago and was normal. Physical examination today reveals normal vital signs and clear skin with faint residual hyperpigmentation on the extensor surfaces. A review of her childhood immunization records confirms completion of the standard pediatric series, including two doses of the measles, mumps, and rubella vaccine. Pre-employment serological testing indicates a negative varicella-zoster virus IgG antibody and a negative hepatitis B surface antibody (anti-HBs). The patient states she never had chickenpox as a child. Which of the following is the most appropriate immunization strategy for this patient?

  1. Initiate the recombinant hepatitis B vaccine series and advise the patient that the varicella vaccine is contraindicatedCevap
  2. B
    Administer both the recombinant hepatitis B vaccine series and the live-attenuated varicella vaccine during this visit
  3. C
    Administer the recombinant zoster vaccine to establish immunity against primary varicella
  4. D
    Administer varicella-zoster immune globulin to provide pre-exposure prophylaxis against varicella
  5. E
    Postpone the hepatitis B vaccine series until adalimumab therapy can be temporarily withheld for at least one month

Cevap

Initiate the recombinant hepatitis B vaccine series and advise the patient that the varicella vaccine is contraindicated
The correct strategy involves initiating the recombinant hepatitis B vaccine series while advising that the varicella vaccine is contraindicated. This patient requires hepatitis B immunization due to her upcoming occupational exposure to human blood, confirmed by her negative surface antibody (anti-HBs). Hepatitis B is an inactivated, recombinant vaccine and is perfectly safe to administer to patients receiving biologic immunosuppressive therapies. In contrast, the patient is also susceptible to varicella (negative VZV IgG). The varicella vaccine is a live-attenuated virus. Adalimumab is a TNF-alpha inhibitor that induces significant systemic immunosuppression. Administration of live-attenuated vaccines (e.g., varicella, measles-mumps-rubella, intranasal influenza) to patients on biologic therapies is absolutely contraindicated due to the high risk of unregulated viral replication and potentially fatal disseminated disease.

Adım Adım Çözüm

1
Evaluate occupational risk factors based on the new employment role.
The patient will handle human blood samples as a laboratory technician.
Healthcare personnel exposed to blood or body fluids must be immune to hepatitis B.
2
Assess the patient's immune status based on serology.
Negative anti-HBs and negative varicella-zoster virus (VZV) IgG.
Identifies susceptibility to both hepatitis B and primary varicella.
3
Review current medications for potential absolute contraindications to standard immunizations.
The patient is actively taking adalimumab, a tumor necrosis factor (TNF)-alpha inhibitor.
Biologic therapies induce significant immunosuppression, fundamentally altering which vaccines can be safely administered.
4
Synthesize indications and contraindications to select the appropriate vaccine strategy.
The inactivated hepatitis B vaccine is safe and indicated, but the live-attenuated varicella vaccine is contraindicated.
Live-attenuated vaccines risk causing unchecked viral replication and severe disseminated disease in immunocompromised hosts.

Anahtar Kavram

Immunization Safety in Immunocompromised Patients
Bu soruyu puanla